undamentalytics Newsletter
Sign in

Denali Therapeutics Inc. insider trading

Every open-market purchase and sale by Denali Therapeutics Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $1.3M 6 trades by 4 insiders 3 months later: median +12.8% (+17.2% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Denali Therapeutics Inc.’s insiders pay?

From February 28, 2020 to September 9, 2026, 11 insiders reported 0 open-market purchases and 80 sales not made under a pre-set plan in Denali Therapeutics Inc. After sales, the shares moved −9.9% against the index over 12 months (a negative figure means selling was the right call).

InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Schuth Alexander O. COFO and Secretary 0 — — 20 −22.8% (18) August 13, 2026
Watts Ryan J. President and CEO 0 — — 17 −19.1% (16) January 8, 2026
Krognes Steve E. CFO and Treasurer 0 — — 16 −23.0% (16) January 8, 2025
Ho Carole Chief Medical Officer 0 — — 15 −22.1% (15) January 8, 2025
Tessier-Lavigne Marc Director 0 — — 4 +23.9% (4) July 27, 2022
Bratton Douglas K 10% owner 0 — — 2 +46.1% (2) February 17, 2021
Crestline Investors, Inc. 10% owner 0 — — 2 +171.3% (2) June 9, 2020
Bratton Capital Inc. 10% owner 0 — — 1 −74.2% (1) December 15, 2020
Bratton Capital Management, L.P. 10% owner 0 — — 1 +169.3% (1) June 30, 2020
Chin Peter Scott Chief Medical Officer 0 — — 1 — September 9, 2026
Crestline Management, LP 10% owner 0 — — 1 +33.2% (1) August 14, 2020

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Denali Therapeutics Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Denali Therapeutics Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 10 selling crowds, −7.9%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
January 31, 20254 selling−23.9%−43.5%−22.4%
August 30, 20244 selling−4.9%−37.4%−56.1%
January 31, 20244 selling−3.0%+32.6%+11.0%
August 31, 20234 selling−21.5%−25.1%−15.5%
January 31, 20234 selling−20.9%−20.5%−68.0%
August 31, 20225 selling+11.7%−2.7%−31.8%
January 31, 20225 selling−18.9%+5.4%−2.5%
August 31, 20214 selling−14.3%−37.1%−36.7%
February 26, 20216 selling−18.7%−48.5%−70.6%
April 30, 20205 selling−2.3%+97.7%+130.5%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Denali Therapeutics Inc. · Funds · Politicians